Short Interest in Ampliphi Biosciences Corp (APHB) Increases By 29.2%
Ampliphi Biosciences Corp (NYSE:APHB) was the recipient of a significant increase in short interest in the month of July. As of July 31st, there was short interest totalling 995,974 shares, an increase of 29.2% from the July 14th total of 770,981 shares. Currently, 11.6% of the shares of the company are sold short. Based on an average trading volume of 1,063,625 shares, the short-interest ratio is presently 0.9 days.
Ampliphi Biosciences Corp (APHB) traded down 6.341% during mid-day trading on Wednesday, reaching $0.768. The company had a trading volume of 196,811 shares. The company’s market capitalization is $5.09 million. The firm’s 50 day moving average price is $1.97 and its 200-day moving average price is $1.02. Ampliphi Biosciences Corp has a 12 month low of $0.30 and a 12 month high of $38.25.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://www.watchlistnews.com/short-interest-in-ampliphi-biosciences-corp-aphb-increases-by-29-2/1466323.html.
Ampliphi Biosciences Corp Company Profile
AmpliPhi Biosciences Corporation is a biotechnology company. The Company is focused on the discovery, development and commercialization of phage therapeutics. The Company is engaged in identifying, characterizing and developing naturally occurring bacteriophages with its collaboration partners in bacteriophage biology, synthetic biology and manufacturing, to develop second-generation bacteriophage products.
Receive News & Ratings for Ampliphi Biosciences Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampliphi Biosciences Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.